Late treatment study
et al., medRxiv, 7/15/2020, doi:10.1101/2020.07.15.20151852 (press release 6/5) (Preprint)
Effect of Hydroxych loroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
RECOVERY trial reports no significant benefit seen for very late stage very sick patients. Results may be due to the unusually high dosage used [1, 2]. Patients were extremely sick (average of 9 days post symptoms, 60% requiring oxygen and an additional 17% requiring ventilation/ECMO), and unusually high death rate was seen in both arms. 1,561 HC
Q patients, 3,155 SOC.
A secondary analysis has found several inconsistencies in the data , and found evidence of excess mortaliy within the first few days that could be due to overdose.
Please send us corrections, updates, or comments.